Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.
Chromosomal translocation t(6;14)(p21.1;q32.3) has been reported as a rare but recurrent event not only in myeloma and plasma cell leukemia but also in diffuse large B-cell non-Hodgkin lymphoma (B-NHL) (diffuse large B-cell lymphoma [DLBCL]) and splenic lymphoma with villous lymphocytes (SLVL); however, the nature of the target gene(s) has not been determined. This study identified t(6;14)(p21.1;q32.3) in 3 cases of transformed extranodal marginal zone B-NHL, in 1 case of SLVL, and in 1 case of a low-grade B-cell lymphoproliferative disorder. In a sixth case, a CD5(+) DLBCL, the translocation was identified by molecular cloning in the absence of cytogenetically detectable change. Two chromosomal translocation breakpoints were cloned by using long-distance inverse polymerase chain reaction methods. Comparison with the genomic sequence for chromosome 6p21.1 showed breakpoints approximately 59 and 73.5 kilobases 5' of the cyclin D3 (CCND3) gene with no other identifiable transcribed sequences in the intervening region. Although Southern blotting with derived genomic 6p21.1 probes failed to detect other rearrangements, fluorescent in situ hybridization assays, using BAC (bacterial artificial chromosome) clones spanning and flanking the CCND3 locus, along with probes for IGH confirmed localization of 6p21.1 breakpoints within the same region, as well as fusion of the CCND3 and IGH loci. Furthermore, in all cases, high-level expression of CCND3 was demonstrated at RNA and/or protein levels by Northern and Western blotting and by immunohistochemistry. These data implicate CCND3 as a dominant oncogene in the pathogenesis and transformation in several histologic subtypes of mature B-cell malignancies with t(6;14)(p21.1;q32.3) and suggest that CCND3 overexpression seen in about 10% of DLBCL cases may have a genetic basis.
Sonoki
T
T
Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, United Kingdom.
Harder
L
L
Horsman
D E
DE
Karran
L
L
Taniguchi
I
I
Willis
T G
TG
Gesk
S
S
Steinemann
D
D
Zucca
E
E
Schlegelberger
B
B
Solé
F
F
Mungall
A J
AJ
Gascoyne
R D
RD
Siebert
R
R
Dyer
M J
MJ
D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000737:chemistry / Q000473:pathology / Q000648:ultrastructure; D001483:Base Sequence; D019457:Chromosome Breakage / Q000235:genetics; D002883:Chromosomes, Human, Pair 14; D002896:Chromosomes, Human, Pair 6; D003001:Cloning, Molecular; D056743:Cyclin D3; D016213:Cyclins / Q000235:genetics*; D005260:Female; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D016393:Lymphoma, B-Cell / Q000737:chemistry / Q000235:genetics* / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D014178:Translocation, Genetic / Q000235:genetics*
C534696:CCND3 protein, human; D056743:Cyclin D3; D016213:Cyclins; D007143:Immunoglobulin Heavy Chains